Sphingosine kinase (SphK) is overexpressed by a variety of cancers, and its phosphorylation of sphingosine results in accumulation of sphingosine-1-phosphate (S1P) and activation of antiapoptotic signal transduction. Existing data indicate a role for S1P in viral pathogenesis, but roles for SphK and S1P in virus-associated cancer progression have not been defined. 
Introduction
Rare and aggressive pathologic variants of diffuse large B-cell lymphoma (DLBCL) arise more frequently in patients infected with the human immunodeficiency virus (HIV), and the majority of these tumors, including primary effusion lymphoma (PEL), are etiologically linked to the human oncogenic γ-herpesviruses: Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) (1) . PEL tumors are causally associated with KSHV, typically infected with both KSHV and EBV (KSHV + EBV + ) or KSHV alone (KSHV + EBV neg ), arise preferentially within pleural or peritoneal cavities, and progress rapidly despite chemotherapy with a median survival of around 6 months (2-4). Combination cytotoxic chemotherapy represents the current standard of care for PEL (3, 5, 6) , but lack of efficacy, off-target effects (including bone marrow suppression), and chemotherapeutic resistance (generated through virus-associated mechanisms) continue to limit the utility of this approach (3, (5) (6) (7) (8) (9) . A combination of highly active antiretroviral therapy (HAART) and rituximab, an anti-CD20 monoclonal antibody, has led to short-term responses, but PEL cells generally do not express CD20 (10, 11) . The proteasome inhibitor bortezomib and the combination of arsenic trioxide and interferon both reduce NF-κB activation and may work synergistically with cytotoxic chemotherapy to reduce PEL viability (12, 13) . Unfortunately, proteasome inhibition and arsenic incur significant toxicities limiting their clinical application.
Antiviral agents inhibit γ-herpesvirus replication (14, 15) , but these drugs do not affect latent gene expression in PEL cell lines and have limited effects on PEL cell growth in vitro (15) . Targeting the mammalian target of rapamycin (mTOR) suppresses constitutive signal transduction associated with PEL survival and has proven successful in pre-clinical models (16) , but rapamycin may paradoxically induce activation of alternative signaling pathways, and whether drug concentrations necessary for an anti-tumoral effect are achievable in patients remains unclear (17) . Finally, data for autologous stem cell transplantation for PEL are also limited, and the problems inherent with additive immune suppression in HIV-infected patients currently preclude routine use of this approach (18) . In summary, safer and more effective therapeutic strategies for PEL are urgently needed.
Sphingolipid biosynthesis involves hydrolytic conversion of ceramide to sphingosine which is subsequently phosphorylated by one of two sphingosine kinase isoforms (SphK1 or SphK2) to generate bioactive sphingosine-1-phosphate (S1P) (19) . The relative cellular concentrations of ceramide and S1P ultimately determine tumor cell fate, with accumulation of ceramides favoring apoptosis, and accumulation of S1P favoring proliferation (19, 20) . SphK is activated by tumorpromoting cytokines and growth factors, leading to rapid increases in the intracellular levels of S1P and depletion of ceramide species (21) . SphK activity and S1P induce activation of signal transduction including mitogen-activated protein kinase (MAPK) and NF-κB pathways (22, 23) relevant to KSHV pathogenesis (24, 25) , and a small number of studies support a role for sphingolipid biosynthetic pathways in regulation of viral pathogenesis (26, 27) . However, functional consequences of targeting SphK and reducing S1P for virus-infected tumor cells have not been explored.
A novel small molecule, 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (ABC294640) inhibits SphK activity and is highly selective for the SphK2 isoform at concentrations less than 100uM (28) . ABC294640 displays in vitro and in vivo activity against a variety of non-viral tumors in preclinical studies, including significant reductions in S1P expression within intratumoral and non-cellular fractions (28, 29) . In addition, the drug's selectivity for SphK, evidenced by lack of inhibition of other kinases (30) , underscores its observed safety in preclinical studies and, thus far, in a clinical trial enrolling patients with solid tumors (Clinicaltrials.gov Identifier: NCT01488513). Therefore, we sought to characterize the impact of ABC294640 inhibition of SphK for KSHV-infected PEL cell viability in vitro, as well as associated tumor progression in vivo, and to identify relationships between SphK inhibition and mechanisms associated with PEL cell death, including induction of apoptosis, accumulation of pro-apoptotic ceramides, and perturbations in KSHV gene expression. Cell viability assays. Metabolic activity of PEL cells was assessed using standard MTT assays as described previously (31) . Apoptosis was quantified by flow cytometry using the FITC-Annexin V/propidium iodide (PI) Apoptosis Detection Kit I (BD Pharmingen) as previously described (10) and according to the manufacturer's instructions. Data were collected using a FACS Calibur 4-color flow cytometer (BD Bioscience).
Materials and Methods

Cell
Transfection assays. BCBL-1 were transfected using pcDNA3.1-FLAG-ERK, pcDNA3.1-FLAG-NF-κB p65, or control vectors as described previously (32, 33) . Transfection efficiency was assessed through co-transfection of a lacZ reporter construct and subsequent determination of β-galactosidase activity using a commercial β-galactosidase enzyme assay system according to the manufacturer's instructions (Promega, Madison, WI). For RNA interference assays, SphK2 ON-TARGET plus SMART pool siRNA (Dharmacon, Chicago, IL), or negative control siRNA, were delivered using the DharmaFECT transfection reagent according to the manufacturer's instructions. To confirm initial transfection efficiency for siRNA experiments, PEL cells were transfected with green fluorescent protein (GFP)-tagged siRNA, and GFP expression determined by flow cytometry 24 h later. Three independent transfections were performed for each experiment, and all samples were analyzed in triplicate for each transfection.
Immunoblotting. Cells were lysed in buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1% NP40, 1 mM EDTA, 5 mM NaF and 5 mM Na 3 VO 4 . Total cell lysates (30 μg) were resolved by 10% SDS-PAGE, transferred to nitrocellulose membranes, and incubated with 100-200 µg/mL of the following antibodies: phospho-Akt (Ser473), phospho-p44/42 ERK (Thr202/Tyr204), phospho-NF-κB p65 (Ser536) and respective total kinase proteins, pro-/cleaved caspase-3, and pro-/cleaved caspase-9 (Cell Signaling Technologies). For loading controls, lysates were also incubated with antibodies detecting β-Actin (Sigma). Immunoreactive bands were developed using an enhanced chemiluminescence reaction (Perkin-Elmer).
qRT-PCR. Total RNA was isolated using the RNeasy Mini kit (QIAGEN), and cDNA was synthesized from equivalent total RNA using a SuperScript III First-Strand Synthesis SuperMix Kit (Invitrogen) according to the manufacturer's instructions. Primers used for amplification of target genes are displayed in Supplemental paired Ct values for β-actin as a loading control, fold changes for experimental groups relative to assigned controls were calculated using automated iQ5 2.0 software (Bio-rad).
Quantification of sphingolipids.
Quantification of ceramide and dihydro-ceramide species was performed using a Thermo Finnigan TSQ 7000 triple-stage quadruple mass spectrometer operating in Multiple Reaction Monitoring positive ionization mode (Thermo Fisher Scientific).
Quantification was based on calibration curves generated by spiking an artificial matrix with known amounts of target standards and an equal amount of the internal standard. The target analyte:internal standard peak area ratios from each sample were compared with the calibration curves using linear regression. Final results were expressed as the ratio of sphingolipid normalized to total phospholipid phosphate level using the Bligh and Dyer lipid extract method (34) . Concentrations of S1P in ascites fluid supernatants and PEL cell lysates were determined using the S1P Assay Kit (Echelon) according to the manufacturers' instructions. Immunohistochemistry. Formalin-fixed, paraffin-embedded tissues were microtome-sectioned to a thickness of 4 uM, placed on electromagnetically charged slides (Fisher Scientific), and stained with hematoxylin & eosin (H&E) for routine histologic analysis. Immunohistochemistry was performed using the Avidin-Biotin-Peroxidase complex system, according to the manufacturer's instructions (Vectastain Elite ABC Peroxidase Kit; Vector Laboratories). In our modified protocol, sections were deparaffinized in xylene and re-hydrated through a descending alcohol gradient. For non-enzymatic antigen retrieval, slides were heated in 0.01 M sodium citrate buffer (pH 6.0) to 95ºC under vacuum for 40 minutes and allowed to cool for 30 minutes at room temperature, then rinsed with PBS and incubated in MeOH/3% H 2 O 2 for 20 minutes to quench endogenous peroxidase. Slides were then washed with PBS and blocked with 5% normal goat serum in 0.1% PBS/BSA for 2 h at room temperature, then incubated overnight with a rat monoclonal anti-LANA antibody (ABI) using a 1:500 dilution in 0.1% PBS/BSA. The following day, slides were incubated with a goat anti-rat IgG secondary antibody at room temperature for 1 h, followed by avidin-biotin peroxidase complexes for 1 h at room temperature. Finally, slides were developed using a diaminobenzidine substrate, counterstained with hematoxylin, dehydrated through an ascending alcohol gradient, cleared in xylene, and coverslipped with Permount.
Images were collected at 200x and 600x magnification using a Olympus BX61 microscope equipped with a high resolution DP72 camera and CellSense image capture software.
Isolation of circulating human B cells. Human peripheral blood mononuclear cells (PBMC)
were isolated from whole blood from two healthy donors following Ficoll gradient separation.
PBMC were washed and resuspended in 500uL total volume, including 440uL buffer composed (28) . We found that the drug induces significant dose-dependent suppression of metabolic activity of BCBL-1 based on MTT assays, with little or no impact on BL-41 cells (Fig. 1A) . Next, using flow cytometry, we found that ABC294640 induces apoptosis in vitro (Fig. 1) . 
To confirm inhibition of SphK in cells for which ABC294640 induces appreciable toxicity, we used mass spectrometry analyses to quantify intracellular levels of bioactive ceramides and dihydro(dh)-ceramides, as well as a modified ELISA assay to quantify S1P. We observed dosedependent accumulation of total ceramide and dh-ceramide levels, and reductions in S1P, within BCBL-1 cells in the presence of ABC294640 (Fig. 2) , thereby confirming dose-dependent inhibition of SphK function in these cells.
ABC294640 induces apoptosis for PEL cell lines through suppression of KSHV-associated signal transduction. As mentioned previously, S1P induces activation of NF-κB and MAPKs, including extracellular signal-regulated kinase (ERK), and these pathways are also activated by KSHV-encoded latent proteins and increase viability for infected cells (22, 23, 32, 35) . Therefore, we sought to determine whether ABC294640 impairs constitutive signal transduction in PEL cells, and whether reversal of drug-induced suppression of these pathways restores PEL viability. We observed dose-dependent suppression of ERK, Akt and NF-κB p65 phosphorylation, as well as cleavage of caspases 3 and 9, within BCBL-1 cells exposed to ABC294640, but not within drugresistant BL-41 cells (Fig. 3A) . To verify whether ABC294640-induced apoptosis is associated with drug-mediated suppression of signal transduction, we transiently transfected BCBL-1 cells with constructs encoding either ERK or p65 prior to their incubation with ABC294640. We found that overexpression of either ERK or p65 (and resultant increases in phospho-ERK/p65) partially suppressed apoptosis induced by ABC294640 (Figs. 3B and C) . To validate these observations, we used RNA interference targeting SphK2 given the preferential inhibitory activity of the drug for this isoform at the concentrations used in our studies. Achieving 60-70% reduction in basal SphK2 transcript expression for BCBL-1 and BCP-1 cells using this approach (Figs. 4A and B) , we found that PEL cells exhibited reduced activation of ERK, Akt and p65 phosphorylation ( experiments, given a high degree of resistance for BCBL-1 cells to conventional cytotoxic agents relative to other PEL cell lines (7) which is due in part to increased surface expression of drug efflux pumps (9) . We observed clear PEL expansion within 3-4 weeks using our protocol, including time-dependent weight gain and increased abdominal girth, as well as ascites accumulation and splenic enlargement due to tumor infiltration at the time of necropsy (Fig. 5 ).
These observations were validated through identification of human CD138 + PEL cells recovered from within ascites fluid (Fig. S2A) , as well as observation of intranuclear expression of KSHVencoded latency-associated nuclear antigen (LANA) within tumor cells from ascites fluid ( Sufficient and homogenous populations of ascites-derived PEL cells were retrievable from drugtreated and untreated mice in these latter experiments for subsequent analyses (Fig. S2) . To assess
SphK inhibition in the model, lipid mass spectrometry was performed using ascites-derived PEL cell lysates from individual animals. Higher concentrations of ceramides and dh-ceramides were observed within live tumor cells from drug-treated animals, although these differences were not significant ( Fig. S3A and B) . However, cells from drug-treated animals exhibited significantly reduced concentrations of intracellular S1P (Fig. S3C) . Lipid mass spectrometry performed on cell-free fluid requires large sample volumes, limiting the utility of this approach for comparison of cell-free intracavitary sphingolipid concentrations between individual animals. Nevertheless, we performed these assays after pooling cell-free ascites fluid, and we observed increases in ceramides and dh-ceramides, as well as reductions in S1P, within pooled samples from ABC294640-treated mice relative to their untreated counterparts (Figs. S3D-F) . Plasma-based assays were also performed, but low concentrations of bioactive sphingolipids in this compartment precluded meaningful comparisons (data not shown).
To determine whether ABC294640 induces apoptosis and suppresses KSHV-associated signal transduction for PEL cells in vivo, we performed immunoblot analyses using ascites-derived PEL (Fig. 6G) .
Discussion
To our knowledge, this is the first report directly implicating bioactive sphingolipids in KSHV pathogenesis. Our data are also consistent with previous reports correlating anti-tumor effects for ABC294640 with intratumoral accumulation of pro-apoptotic ceramide species, reduced S1P levels, and suppression of MAPK and NF-κB activation (28, 29, 38, 39) . One recent study reported induction of autophagy within renal, prostate, and breast cancer cell lines following exposure to ABC294640, and use of an inhibitor of autophagy enabled apoptosis while reducing tumor cell death with ABC294640 exposure (40) . These data suggest that for some tumors, 
drug treatment only partially restored PEL viability, and we observed coincident dose-dependent activation of viral lytic gene expression with the drug. Induction of KSHV lytic gene expression, governed by the lytic "switch" gene ORF50, typically results in PEL cell death (42) (43) (44) , and this concept has been explored as a therapeutic strategy given that standard cytotoxic agents, as well as bortezomib and valproic acid (the latter a histone deacetylase inhibitor used for a variety of clinical applications), induce lytic gene expression and reduce PEL cell viability (36, 37, 42, 45) .
KSHV lytic gene expression is inhibited through histone deacetylase (HDAC) binding to ORF50, (46) , and viral genes expressed predominantly during lytic replication suppress HDAC activity (47) . A role for SphK in epigenetic regulation was revealed through its direct association with core histone H3 and generation of intranuclear S1P which binds active sites on HDACs to inhibit their enzymatic activity (48) . These data suggest a potential role for SphK and S1P in regulating the KSHV lytic switch. Since KSHV microRNAs also regulate the lytic switch, induce antiapoptotic signal transduction, promote viral latency, and suppress caspase-3-mediated apoptosis for KSHV-infected cells (49) (50) (51) (52) (53) , future mechanistic studies might logically focus on whether SphK and S1P regulate KSHV microRNA expression and function. Whether the observed lack of toxicity for KSHV neg /EBV neg BL-41 cells and human peripheral B cells isolated from healthy donors in our studies is related to the lack of established viral infection within these cells (and, by extension, lack of induction of death-associated lytic viral gene expression) requires confirmation.
Additional studies are also needed to address potential mechanisms for drug resistance, including drug transporter expression or compensatory signaling associated with cellular oncogenes.
ABC294640 exhibits little or no inhibitory activity for SphK1 at concentrations up to 100uM (28) , a concentration that exceeds those used in our in vitro studies. Moreover, we find that RNAi targeting of SphK2 alone is sufficient to suppress ERK, Akt and NF-κB activation and induce apoptosis for PEL cells. Induction of apoptosis with SphK2 knockdown was incomplete, although this could reflect limitations of our assays given low-level persistence of SphK2 transcripts and protein with our siRNA protocol. Therefore, while we feel it is unlikely that ABC294640 reduces S1P production in PEL cells through inhibition of SphK1 at clinically achievable concentrations, we cannot categorically exclude drug inhibition of SphK1 as a mechanism for the observations in the present studies.
S1P binds to one of five G protein-coupled S1P receptors (S1PR1-5) that activate diverse downstream signaling pathways (54) . Our identification of extracellular S1P within ascites fluid from tumor-bearing mice suggests that PEL cells may support their own growth through secretion of S1P and augmentation of signal transduction through autocrine or paracrine mechanisms. Therefore, additional experiments are underway to characterize S1PR expression by PEL cells and to determine their relative importance for constitutive PEL signaling, as well as the role for exogenous S1P in survival for KSHV-infected cells. Our data also indicate that S1P may be useful as either a diagnostic tool or prognostic biomarker in ascites fluid, and future clinical trials including these assays should provide additional information.
Collectively, our data imply that SphK (specifically SphK2) and S1P play a role in PEL 
